Han W. Tun, M.D.

Location

  1. Jacksonville, Fl
  • Lymphoma
  • Primary central nervous system lymphoma
  • Chronic lymphatic leukemia
  • Bone marrow transplantation
  1. 2001
    Fellow - Hematology/OncologyMayo Clinic in Florida
  2. 1998
    Chief Resident - Post Graduate Year III Chief Residency in Internal MedicineHarbor Hospital Center
  3. 1997
    Resident - Post Graduate Year I-II Internal Medicine ResidencyHarbor Hospital Center
  4. 1995
    Senior House Officer - Training in Geriatric MedicineNorthampton General Hospital
  5. 1995
    House Officer - House Officer Training in Psychiatry/Geriatric Medicine (four institutions)Queen Elizabeth Hospital
  6. 1995
    House Officer - House Officer Training in Psychiatry/Geriatric Medicine (four institutions)All Saints Hospital
  7. 1995
    House Officer - House Officer Training in Psychiatry/Geriatric Medicine (four institutions)Northampton General Hospital
  8. 1993
    Senior House Officer - Training in PsychiatrySt. Cadoc Hospital

Certifications

  1. American Board of Internal Medicine - Medical Oncology
  2. American Board of Internal Medicine
  3. American Board of Internal Medicine - Hematology

Professional Highlights

  1. Discovery of CNS signature of primary CNS lymphoma with osteopontin as the most upregulated gene compared to non-CNS diffuse large B cell lymphoma
  2. Demonstration of osteopontin as a multi-faceted protumorigenic driver mediating intracerebral tumor growth, invasion, and dissemination in CNS lymphoma via activation of NF-KB by a novel mechanism involving secretory and intracellular osteopontin
  3. US patent on agelastatin A and its analogues for therapeutic use in treatment of primary and secondary brain tumors ("IMIDAZO[4',5':4,5]CYCLOPENTA[1,2-e]PYRROLO[1,2-A]PYRAZINES and OXAZOLO[4',5':4,5]cyclopenta[1,2-e]PYRROLO[1,2-A]PYRAZINES FOR TREATING BRAIN CANCER") (PCT/US2013/064605; approval date 6/7/2016). These compounds have shown significant therapeutic activity against CNS lymphoma, glioblastoma multiforme, and metastatic triple negative breast cancer of the brain in pre-clinical models. The compounds were developed in collaboration with Professor Takehiko Yoshimitsu at Osaka University
  4. Demonstration of conversion of M2 tumor associated macrophages (TAMs) to M1 phenotype by pomalidomide
  5. Demonstration of pathway signature and adipogenic cellular differentiation in clear cell renal cell carcinoma

Publications

Research Activities

See a description of research activities.